Scholarlink

Purpose of Review <p>Steroid-sparing immunomodulatory agents (SSIAs) are frequently used to treat steroid-refractory immune related adverse events (irAEs) from immune checkpoint inhibitors (ICIs). This paper aims to review the evidence supporting the use of particular SSIAs for different irAEs, and practical considerations for choosing between SSIAs including unique toxicity profiles, infectious considerations, and cost implications.</p> Recent Findings <p>SSIAs have been shown to be effective for steroid-refractory irAEs in multiple case series and some clinical trials, but there is limited prospective evidence comparing the efficacy of one SSIA to another.</p> Summary <p>Effective treatment of irAEs is essential to improving patient outcomes. This article aims to help clinicians understand the data behind available SSIAs, and understand drug-specific considerations that may influence the choice of SSIAs in different situations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Utilization of Steroid Sparing Agents for Immune-Related Adverse Events (irAEs): Management Strategies and Considerations

  • 期刊论文

  • 发表日期：

    2026年2月7日

查看全文
  • Sherin J. Rouhani,
  • Matthew J. Hadfield,
  • Matthew Lei,
  • Ross D. Merkin,
  • Michael Dougan,
  • Gabriela S. Hobbs,
  • Sarah P. Hammond,
  • Kerry L. Reynolds

摘要

Purpose of Review

Steroid-sparing immunomodulatory agents (SSIAs) are frequently used to treat steroid-refractory immune related adverse events (irAEs) from immune checkpoint inhibitors (ICIs). This paper aims to review the evidence supporting the use of particular SSIAs for different irAEs, and practical considerations for choosing between SSIAs including unique toxicity profiles, infectious considerations, and cost implications.

Recent Findings

SSIAs have been shown to be effective for steroid-refractory irAEs in multiple case series and some clinical trials, but there is limited prospective evidence comparing the efficacy of one SSIA to another.

Summary

Effective treatment of irAEs is essential to improving patient outcomes. This article aims to help clinicians understand the data behind available SSIAs, and understand drug-specific considerations that may influence the choice of SSIAs in different situations.